The main study purpose is to demonstrate the non-inferiority of T4032 compared to Lumigan® 0.01% in terms of efficacy.

Inclusion Criteria:

• Informed consent dated and signed.
• Both eyes diagnosed open-angle glaucoma or ocular hypertension

Exclusion Criteria:

• History of trauma, infection, clinically significant inflammation within the previous 3 months
• Known or suspected hypersensitivity to one of the components of the Investigational Medicinal Product(s)
• Pregnancy or breast-feeding